【摘要】 目的 探讨非小细胞肺癌(non-small cell lung cancer,NSCLC)患者临床分期相关的危险因素。方法 回顾性分析2019年7月至2023年3月收治的182例NSCLC患者的临床资料,根据患者临床分期分为Ⅰ期、Ⅱ期组和Ⅲ期、Ⅳ期组,通过组间比较结合Logistic回归分析筛选影响患者临床分期的危险因素,并采用受试者操作特征(receiver operating characteristic,ROC)曲线分析其在患者临床分期中的诊断价值。结果 抗核抗体(antinuclear antibody,ANA)、纤维蛋白原(fibrinogen,FIB)和细胞角蛋白19片段(cytokeratin 19 fragment,CYFRA21-1)是影响NSCLC患者临床分期的独立危险因素,FIB与CYFRA21-1的最佳截断值分别为4.07g/L和7.07μg/L,3个项目联合诊断患者临床分期的AUC为0.859,敏感度为64.2%,特异性为95.9%。结论 ANA、FIB和CYFRA21-1是影响NSCLC患者临床分期的独立危险因素,3个指标联合检测对NSCLC患者临床分期的诊断有一定的参考价值。更多还原

【Abstract】 Objective To investigate the risk factors associated with clinical stage in patients with non-small cell lung cancer(NSCLC). Methods The clinical data of 182 patients with non-small cell lung cancer admitted from July 2019 to March 2023 were retrospectively analyzed, and they were divided into stage Ⅰ, stage Ⅱ group(n=73) and stage Ⅲ, stage Ⅳ group(n=109)according to the clinical stage. Inter-group comparison and Logistic regression analysis were used to screen the risk factors affecting the clinical stage of patients, and receiver operating characteristic( ROC) curve was used to analyze the diagnostic value of these risk factors. Results Antinuclear antibody(ANA), fibrinogen(FIB) and cytokeratin 19 fragment(CYFRA21-1)were independent risk factors affecting the clinical stage of NSCLC patients. The optimal cut-off values of FIB and CYFRA21-1 were 4.07g/L and 7.07μg/L, respectively. The area under curve(AUC) of the combined diagnosis of clinical stage was 0.859, the sensitivity was 64.2%, and the specificity was 95.9%. Conclusion ANA, FIB and CYFRA21-1 are independent risk factors for the progression of clinical stage of NSCLC patients. The combined detection of the three indicators has certain reference value for the diagnosis of clinical stage in NSCLC patients.更多还原